Health

Drug Developer Dyne Therapeutics Weigh Options After Takeover Interest

Drug developer draws takeover interest following positive data
Company’s shares soar more than 40% in New York trading

Dyne raised $345 million in an equity offering earlier this month, after its shares surged on promising data from early-stage trials of two therapies. — Dyne raised $345 million in an equity offering earlier this month, after its shares surged on promising data from early-stage trials of two therapies.
Photographer: Eric Baradat/AFP/Getty Images

Provide news feedback or report an error

Confidential tip?

Send a tip to our reporters

Site feedback:

Take our Survey

By Dinesh Nair and Michelle F Davis

January 26, 2024 at 7:30 PM UTC

Updated on

January 26, 2024 at 8:31 PM UTC

This article is for subscribers only.

Dyne Therapeutics Inc. shares surged more than 40% after people with knowledge of the matter said the developer of drugs to treat muscle diseases has received takeover interest from larger pharmaceutical companies.

The Waltham, Massachusetts-based company has been speaking with advisers as it considers options including a possible sale or partnership, according to the people, who asked not to be identified discussing confidential information.